Toa Eiyo Ltd.

Shin-ichi Kazayama

Hideki Yamada

Atsuo Takahashi

Hidekazu Masaki

Takeshi Hasegawa

Koichi Takayanagi

Fumiya Yoneyama

Takahiro Morita

Shoji Satoh

Tetsuo Kuze

Yusuke Mizuno

Mizuo Miyazaki

Akira Tatsui

Shinji Takai

Kazuhiro Uemoto

Shin-ya Ohnuma

The present invention relates to a medicine, particularly a medicine comprising a novel cyclohepta[b]pyridine-3-carbonylguanidine derivative having an inhibitory effect on an Na/Hexchanger (NHE). There is provided a cyclohepta[b]pyridine-3-carbonylguanidine derivative represented by Formula (1): wherein Ris a group selected from a sulfo group, a sulfoxy group, &#x2014;OCONH&#x2014;(CHCHO)&#x2014;SOH and the following formulas: Rrepresents a halogen atom, a lower alkyl group or a lower alkoxy group; and n represents an integer from 1 to 10,

Cyclohepta[b]pyridine-3-carbonylguanidine derivative and pharmaceutical product containing same

The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

N-substituted benzothiophenesulfonamide derivatives

A halogenobenzylaminopropionic acid derivative represented by the following formula (1):or a pharmaceutically acceptable salt of the derivative, and a drug containing the same as an active ingredient for treating diabetes, hyperlipidemia, or similar pathological conditions.

Halogenobenzyl aminopropionic acid derivatives

Growing community of inventors

Saitama, Japan

Shin-ichi Kazayama